Radiopharmaceutical developer Molecular Insight Pharmaceuticals has begun a phase II clinical trial of its technetium-99m (Tc-99m) MIP-1404 prostate cancer molecular imaging agent.
The agent is designed to detect the location and extent of prostate cancer in men who are newly diagnosed or have recurrent or progressive disease, according to the vendor. The phase II, international, multicenter, open-label study will include as many as 120 high-risk prostate cancer patients scheduled for a clinically-indicated prostatectomy and extended pelvic lymph node dissection, Molecular Insight said.
Patients will receive a single intravenous dose of Tc-99m MIP-1404 followed by a SPECT/CT scan three to six hours after administration and again within three weeks of scheduled prostatectomy and extended pelvic lymph node dissection. The company-sponsored trial will be conducted at approximately 10 sites in the U.S. and approximately 25 sites in Western, Central, and Eastern Europe.
